Stay updated with the Dr Reddys Stock Liveblog, your one-stop destination for real-time information and analysis of a leading ...

Dr. Reddy's Laboratories Ltd. 500124 shares slipped 2.23% to 1,197.40 Indian rupees Monday, on what proved to be an ...

Barclays analyst Balaji Prasad maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report) today and set a price target of ...

Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after ...

Shares of Dr Reddy's Laboratories fell by 5% as the company's third-quarter profit rise failed to impress investors. The ...

Dr. Reddy's Laboratories Ltd. 500124 shares slid 5.01% to 1,224.70 Indian rupees Friday, on what proved to be an all-around ...

(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...

CEO of Dr Reddy's Laboratories, Erez Israeli believes his company's affordable medicines benefit the U.S. market and will be ...

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.

Ladies and gentlemen, good day and welcome to the Quarter Three FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only ...

FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.

HYDERABAD, India (AP) — HYDERABAD, India (AP) — Dr. Reddy's Laboratories Ltd. (RDY) on Thursday reported profit of $167.3 million in its fiscal third quarter. The Hyderabad, India-based company said ...